Biological
Setrusumab
Setrusumab is a biological therapy with 5 clinical trials. Currently 3 active trials ongoing. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
3(60%)
Results Posted
200%(2 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_3
2
40%
Ph phase_2
3
60%
Phase Distribution
0
Early Stage
3
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
3
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Completed(1)
Terminated(1)
Detailed Status
Active, not recruiting3
Terminated1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
3
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (60.0%)
Phase 32 (40.0%)
Trials by Status
active_not_recruiting360%
terminated120%
completed120%
Recent Activity
3 active trials
Showing 5 of 5
active_not_recruitingphase_3
Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
NCT06636071
active_not_recruitingphase_2
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809
active_not_recruitingphase_3
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
NCT05768854
terminatedphase_2
Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
NCT05312697
completedphase_2
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
NCT03118570
Clinical Trials (5)
Showing 5 of 5 trials
NCT06636071Phase 3
Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
NCT05125809Phase 2
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05768854Phase 3
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
NCT05312697Phase 2
Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
NCT03118570Phase 2
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5